{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:21:53Z","timestamp":1780082513721,"version":"3.54.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.aohep.2023.101185","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T07:58:50Z","timestamp":1701417530000},"page":"101185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America."],"prefix":"10.1016","volume":"29","author":[{"given":"Federico","family":"Pi\u00f1ero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Casciato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2023.101185_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.aohep.2023.101185_bib0004","unstructured":"Fact Sheets by Population-Globocan-IARC [Internet]. Disponible en: http:\/\/globocan.iarc.fr\/Pages\/factsheets population.aspx, 2020."},{"key":"10.1016\/j.aohep.2023.101185_bib0005","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.11.020","article-title":"Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012","volume":"152","author":"White","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.101185_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.aohep.2023.101185_bib0007","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention","volume":"70","author":"Liu","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0008","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of Hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pi\u00f1ero","year":"2019","journal-title":"Liver International"},{"key":"10.1016\/j.aohep.2023.101185_bib0011","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/liv.13502","article-title":"Hepatocellular carcinoma in South America: evaluation of risk factors, demographics and therapy","volume":"38","author":"Debes","year":"2018","journal-title":"Liver International"},{"key":"10.1016\/j.aohep.2023.101185_bib0013","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5604\/01.3001.0010.8648","article-title":"Results of liver transplantation for hepatocellular carcinoma in a multicenter Latin American Cohort Study","volume":"17","author":"Pi\u00f1ero","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100876","article-title":"Changing epidemiology of hepatocellular carcinoma in South America: a report from the South American liver research network","volume":"28","author":"Farah","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.101185_bib0016","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"New England J Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0017","first-page":"2021","article-title":"Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"5","author":"Memel","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2023.101185_bib0018","volume":"39","author":"Khan","year":"2019"},{"key":"10.1016\/j.aohep.2023.101185_bib0019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bpg.2016.10.006","article-title":"Surveillance for hepatocellular carcinoma","volume":"30","author":"D\u00edaz-Gonz\u00e1lez","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.aohep.2023.101185_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0022","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0023","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0024","first-page":"1","article-title":"Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions","volume":"0","author":"Innes","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.20517\/2394-5079.2022.22","article-title":"Cholangiocarcinoma: early detection and screening in high-risk population","volume":"8","author":"Mu\u00f1oz-Mart\u00ednez","year":"2022","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.aohep.2023.101185_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.110911","article-title":"A gadoxetic-acid enhancement flux analysis of small liver nodules (\u22642m) in patients at high risk of hepatocellular carcinoma","volume":"165","author":"Chen","year":"2023","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0027","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/liv.14133","article-title":"Prospective evaluation of gadoxetic-acid MR for the diagnosis of HCC in newly detected nodules \u2264 2cm in cirrhosis","volume":"39","author":"Ayuso","year":"2019","journal-title":"Liver International"},{"key":"10.1016\/j.aohep.2023.101185_bib0028","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jhep.2019.12.011","article-title":"Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs","volume":"72","author":"Paisant","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0029","unstructured":"American College of Radiology. Liver imaging reporting and data system version 2018. Accessed March 12 2020, from https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-2018-Core.pdf?la=en n.d."},{"key":"10.1016\/j.aohep.2023.101185_bib0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1148\/radiol.2021211244","article-title":"CT\/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma: individual patient data meta-analysis","volume":"302","author":"van der Pol","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2023.101185_bib0031","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RCT.0000000000000945","article-title":"Interobserver agreement of magnetic resonance imaging of liver imaging reporting and data system version 2018","volume":"44","author":"Razek","year":"2020","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.aohep.2023.101185_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32494","article-title":"Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria","author":"Rimola","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0033","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1007\/s00330-020-07457-6","article-title":"Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules \u2264 2cm in cirrhotic patients","volume":"31","author":"Darnell","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0034","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.aohep.2020.06.007","article-title":"LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: a prospective cohort study","volume":"19","author":"Pi\u00f1ero","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0035","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0036","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0037","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrclinonc.2014.122","article-title":"Treatment of intermediate-stage hepatocellular carcinoma","volume":"11","author":"Forner","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0038","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/hep.24670","article-title":"Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques","volume":"54","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041244","article-title":"New challenges in the management of cholangiocarcinoma: the role of liver transplantation, locoregional therapies, and systemic therapy","volume":"15","author":"Mauro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.aohep.2023.101185_bib0040","series-title":"American joint committee on cancer. ajcc cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.aohep.2023.101185_bib0041","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0042","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0043","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00464-017-5930-1","article-title":"Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study","volume":"32","author":"Molina","year":"2018","journal-title":"Surg Endosc"},{"key":"10.1016\/j.aohep.2023.101185_bib0044","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/bjs.10137","article-title":"Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma","volume":"103","author":"Sposito","year":"2016","journal-title":"Br J Surg"},{"key":"10.1016\/j.aohep.2023.101185_bib0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jhbp.215","article-title":"Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease","volume":"22","author":"Morise","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.aohep.2023.101185_bib0046","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/SLA.0000000000003192","article-title":"Liver resection for multiple hepatocellular carcinomas: a japanese nationwide survey","volume":"272","author":"Fukami","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.aohep.2023.101185_bib0047","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.03.009","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.aohep.2023.101185_bib0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2023.101185_bib0051","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0052","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/jlts.2002.34892","article-title":"Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.aohep.2023.101185_bib0053","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/hep.22693","article-title":"Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database","volume":"49","author":"Toso","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0054","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for Hepatocellular Carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.101185_bib0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"65","author":"Xu","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2023.101185_bib0056","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/tri.12274","article-title":"Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma","volume":"27","author":"Shindoh","year":"2014","journal-title":"Transplant International"},{"key":"10.1016\/j.aohep.2023.101185_bib0057","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1600-6143.2009.02783.x","article-title":"Significance of Des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma","volume":"9","author":"Fujiki","year":"2009","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.aohep.2023.101185_bib0058","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/lt.24117","article-title":"Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation","volume":"21","author":"Chaiteerakij","year":"2015","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.aohep.2023.101185_bib0059","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/lt.21368","article-title":"Liver transplantation in patients with hepatocellular carcinoma across Milan criteria","volume":"14","author":"Herrero","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.aohep.2023.101185_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0061","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.101185_bib0062","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2020.03.018","article-title":"Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant","volume":"73","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0063","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/tri.13767","article-title":"Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region","volume":"34","author":"Pi\u00f1ero","year":"2021","journal-title":"Transplant Int"},{"key":"10.1016\/j.aohep.2023.101185_bib0064","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/liv.13417","article-title":"Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: still an unmet need","volume":"37","author":"Pi\u00f1ero","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2023.101185_bib0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamasurg.2021.0954","article-title":"Dynamic \u03b1-Fetoprotein response and outcomes after liver transplant for hepatocellular carcinoma","volume":"156","author":"Halazun","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.aohep.2023.101185_bib0066","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jhep.2021.06.015","article-title":"Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival","volume":"75","author":"Ferrer-F\u00e0brega","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0067","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jclinepi.2008.04.008","article-title":"Validation, updating and impact of clinical prediction rules: a review","volume":"61","author":"Toll","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0068","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/EDE.0000000000000018","article-title":"Net reclassification indices for evaluating risk-prediction instruments: a critical review","volume":"25","author":"Kerr","year":"2014","journal-title":"Epidemiology"},{"key":"10.1016\/j.aohep.2023.101185_bib0069","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","article-title":"Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis","volume":"122","author":"Schuster","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100644","article-title":"AFP score and metroticket 2.0 perform similarly and could be used in a \u201cwithin-ALL\u201d clinical decision tool","volume":"5","author":"Pi\u00f1ero","year":"2023","journal-title":"JHEP Reports"},{"key":"10.1016\/j.aohep.2023.101185_bib0072","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0073","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1470-2045(20)30333-8","article-title":"Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?","volume":"21","author":"Ferrer-F\u00e0brega","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0074","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/lt.20526","article-title":"A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation","volume":"11","author":"Yao","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.aohep.2023.101185_bib0075","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.30879","article-title":"National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time","volume":"71","author":"Mehta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0076","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.101185_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020452","article-title":"Identification of an upper limit of tumor burden for downstaging in candidates with hepatocellular cancer waiting for liver transplantation: a west\u2013east collaborative effort","volume":"12","author":"Lai","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.aohep.2023.101185_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100331","article-title":"International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria","volume":"3","author":"Degroote","year":"2021","journal-title":"JHEP Reports"},{"key":"10.1016\/j.aohep.2023.101185_bib0079","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","volume":"76","author":"Tran","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11605-007-0335-4","article-title":"Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period","volume":"12","author":"Becker","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.aohep.2023.101185_bib0081","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0082","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1097\/TP.0000000000003539","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates","volume":"105","author":"Ziogas","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.aohep.2023.101185_bib0083","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2023.101185_bib0084","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/lt.26285","article-title":"A 3-decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy","volume":"28","author":"Ito","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.aohep.2023.101185_bib0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2023.101185_bib0086","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0087","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0088","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","article-title":"Chemoembolization With Doxorubicin-Eluting Beads for unresectable hepatocellular carcinoma: five-year survival analysis","volume":"35","author":"Malagari","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0089","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION v study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0090","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0091","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/bjc.2013.85","article-title":"A randomised phase II\/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma","volume":"108","author":"Meyer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.aohep.2023.101185_bib0092","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000365993","article-title":"Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization","volume":"87","author":"Ogasawara","year":"2014","journal-title":"Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2023.101185_bib0093","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000368143","article-title":"Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ","volume":"87","author":"Arizumi","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.aohep.2023.101185_bib0094","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0095","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0096","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0097","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2023.101185_bib0098","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0099","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final Results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2023.101185_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a Phase III, Randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0101","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0102","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0103","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: european experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.aohep.2023.101185_bib0104","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0105","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0168-8278(17)30436-1","article-title":"SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma","volume":"66","author":"Vilgrain","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0106","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0107","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH Study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2023.101185_bib0108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0109","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0111","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2023.101185_bib0112","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE Phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2023.101185_bib0113","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.3390\/cancers13215399","article-title":"Outcome and safety after 103 radioembolizations with Yttrium-90 resin microspheres in 73 patients with unresectable intrahepatic cholangiocarcinoma-an evaluation of predictors","volume":"13","author":"Paprottka","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.aohep.2023.101185_bib0114","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","article-title":"Intrahepatic cholangiocarcinoma treated with transarterial Yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study","volume":"29","author":"Gangi","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2020.02.008","article-title":"Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis","volume":"31","author":"Buettner","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0116","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","article-title":"Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis","volume":"24","author":"Mouli","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0117","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s00259-019-04427-z","article-title":"Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study","volume":"46","author":"Levillain","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.aohep.2023.101185_bib0118","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","article-title":"Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study","volume":"43","author":"Bargellini","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0119","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jvir.2019.03.018","article-title":"Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study","volume":"30","author":"White","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.aohep.2023.101185_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010056","article-title":"Prognostic factors for overall survival in advanced intrahepatic cholangiocarcinoma treated with Yttrium-90 radioembolization","volume":"9","author":"K\u00f6hler","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0121","article-title":"Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials","author":"Edeline","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0122","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0124","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.aohep.2023.101185_bib0125","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.aohep.2023.101185_bib0126","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.aohep.2023.101185_bib0127","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"New England J Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0128","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4003","article-title":"REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe","volume":"36","author":"Zhu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0129","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Eviden"},{"key":"10.1016\/j.aohep.2023.101185_bib0130","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0131","doi-asserted-by":"crossref","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","article-title":"LBA36 Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"33","author":"Qin","year":"2022","journal-title":"Annals Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0132","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"0","author":"Qin","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.aohep.2023.101185_bib0133","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0134","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.aohep.2023.101185_bib0135","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0136","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/liv.14436","article-title":"International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis","volume":"40","author":"D\u00edaz-Gonz\u00e1lez","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2023.101185_bib0137","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep4.1523","article-title":"Regorafenib versus nivolumab after sorafenib failure: real-world data in patients with hepatocellular carcinoma","volume":"4","author":"Choi","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2023.101185_bib0138","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/liv.15502","article-title":"Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: an international observational study","volume":"43","author":"Talbot","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2023.101185_bib0139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.aohep.2023.101185_bib0140","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0141","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v26.i16.1888","article-title":"Sequencing of systemic treatment for hepatocellular carcinoma: second line competitors","volume":"26","author":"Pi\u00f1ero","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2023.101185_bib0142","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101110","article-title":"Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC","volume":"28","author":"Pi\u00f1ero","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0143","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"issue":"In Press","key":"10.1016\/j.aohep.2023.101185_bib0144","article-title":"Outcome of patients with hepatocellular carcinoma and liver dysfunction under immunotherapy: a Systematic review and meta-analysis","author":"El Hajra","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101185_bib0145","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL-ILCA clinical practice guidelines on intrahepatic cholangiocarcinoma","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0147","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0148","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.aohep.2023.101185_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"suppl_7","key":"10.1016\/j.aohep.2023.101185_bib0150","first-page":"S19","article-title":"Updated overall survival from the phase 3 TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in patients with advanced biliary tract cancer. (Abstract 56P)","volume":"33","author":"Oh","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.aohep.2023.101185_bib0151","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.aohep.2023.101185_bib0152","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0153","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0154","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2023.101185_bib0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0157","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0158","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0159","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101185_bib0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a Phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.aohep.2023.101185_bib0161","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2023.101185_bib0162","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268123002880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268123002880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T19:32:14Z","timestamp":1714159934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268123002880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":162,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1665268123002880"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2023.101185","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2023.101185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101185"}}